RxDoctor Payments Data

Kelly Goodman, NP

Adult Health · Bethesda, MDNPI 1639396914

Payments from drug & device makers

$2,652in general payments, 2019–2025

Across 89 payments — averaging $29.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Axsome Therapeutics, Inc.$176
  • Revance Therapeutics, Inc.$151
  • Novo Nordisk$149
  • Phathom Pharmaceuticals, Inc.$140
  • Therapeuticsmd, Inc.$123
  • plus $667 from 17 others

What the payments were for

  • Food & beverage$2,652100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,652 in reported general payments places this provider in the 80th percentile of 542 adult health providers in Maryland.

See all adult health providers in Maryland

Medicare billing

Part B allowed, 2024
$315,398
Medicare patients
727
Services billed
4,280

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab11$48,612
OzempicSemaglutide29$27,040
SynthroidLevothyroxine Sodium42$2,959
Celecoxib41$2,519
Rosuvastatin Calcium179$2,019
Zolpidem Tartrate191$1,972
Levothyroxine Sodium149$1,712
Duloxetine Hcl48$1,524
Escitalopram Oxalate71$1,454
PaxlovidNirmatrelvir/Ritonavir13$1,368
Atorvastatin Calcium142$1,348
Estradiol30$1,184
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine23$1,182
Gabapentin49$872
ValacyclovirValacyclovir Hcl19$806

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$149$27,04029 claims
AbbVieSynthroid$1,245$2,95942 claims
PfizerPaxlovid$95$1,36813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 542 adult health providers in Maryland.

Other adult health in Bethesda

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →